Notably, CXCL16 (a ligand) from tumor cells and CXCR6 (a receptor) on HLA-DR+CD38+CD8+ T cells—previously implicated in enhancing anti-PD-1 therapy efficacy in other cancers—may mediate key tumor‒immune interactions.21,22. This evidence concerns the gene CD38 and neoplasm.